AI assistant
DELTEX MEDICAL GROUP PLC — Director's Dealing 2017
Mar 22, 2017
7593_rns_2017-03-22_27afcc00-0c93-4e24-9baa-7ba8d0aa7701.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1455A
Deltex Medical Group PLC
22 March 2017
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).
22 March 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), today announces that the Board has approved the issue of share options to Ewan Phillips, Chief Executive and Jonathan Shaw, Group Finance Director.
Employee Share Option Scheme
The Board has approved the issue of 658,743 and 404,762 share options to Ewan Phillips and Jonathan Shaw, respectively under the Company's 2003 Share Option Scheme ("EMI"). The exercise price is 1 pence per share option.
The awards were made in return for the directors agreeing to waive gross salary and benefits of £17,292 and £10,625 respectively.
Confirmation of Directors interest in share options
Following the grant of EMI options above, the options held by the Executive Directors are shown below:
| Executive Director | 2001 Executive Share Scheme | 2011 Executive Share Scheme | EMI Share Scheme | Total |
| Number | Number | Number | Number | |
| Ewan Phillips | 1,400,000 | 2,750,000 | 2,995,954 | 7,145,954 |
| Jonathan Shaw | - | - | 404,762 | 404,762 |
Additional interests
Following the Subscription announced this morning, Mr Phillips will have a beneficial interest in 2,921,051 ordinary shares in the Company representing 0.98 per cent of the issued ordinary share capital of the Company. Mr Shaw will have a beneficial interest in 262,931 ordinary shares in the Company representing 0.09 per cent of the issued ordinary share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The following notifications are made in accordance with Article 19 of the EU Market Abuse Regulation
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Ewan Phillips |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Director |
| b) | Initial notification /Amendment | Initial |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Deltex Medical Group plc |
| b) | LEI | N/A |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code |
Unconditional awards over Ordinary shares of 1p each in Deltex Medical Group plc Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583 |
| b) | Nature of the transaction | Share subscription |
| c) | Price(s) and volume(s) | Unconditional award over 658,743 shares under the Deltex Medical 2003 Share Option Scheme |
| d) | Aggregated information - Aggregated volume - Price |
|
| e) | Date of the transaction | 22 March 2017 |
| f) | Place of the transaction | Grant of share awards occurred outside of a trading venue. |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Jonathan Shaw |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Director |
| b) | Initial notification /Amendment | Initial |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Deltex Medical Group plc |
| b) | LEI | N/A |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code |
Unconditional awards over Ordinary shares of 1p each in Deltex Medical Group plc Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583 |
| b) | Nature of the transaction | Share subscription |
| c) | Price(s) and volume(s) | Unconditional award over 404,762 shares under the Deltex Medical 2003 Share Option Scheme |
| d) | Aggregated information - Aggregated volume - Price |
|
| e) | Date of the transaction | 22 March 2017 |
| f) | Place of the transaction | Grant of share awards occurred outside of a trading venue. |
For further information, please contact:-
| Deltex Medical Group plc | 01243 774 837 [email protected] |
| Nigel Keen, Chairman | |
| Ewan Phillips, Chief Executive | |
| Jonathan Shaw, Group Finance Director | |
| Nominated Adviser & Broker | |
| Arden Partners plc | 020 7614 5900 |
| Chris Hardie | |
| Financial Public Relations | |
| IFC Advisory Ltd | 0203 053 8671 |
| Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLFFELVRILFID